Table S3 Week 16 and 52 efficacy endpoints for patients treated continuously with ixekizumab: COAST-V and COAST-W (ITT: observed data)

	COAST-V (bDMARD-naïve)				COAST-W (TNFi-experienced)			
	IXE Q4W (N=81)		IXE Q2W (N=83)		IXE Q4W (N=114)		IXE Q2W (N=98)	
Patients achieving response, n (%)	Week 16	Week 52	Week 16	Week 52	Week 16	Week 52	Week 16	Week 52
ASAS40	39/78 (50.0)	43/72 (59.7)	43/81 (53.1)	42/74 (56.8)	29/100 (29.0)	39/88 (44.3)	30/91 (33.0)	30/80 (37.5)
ASAS20	52/78 (66.7)	53/72 (73.6)	57/81 (70.4)	59/74 (79.7)	55/100 (55.0)	60/88 (68.2)	46/91 (50.5)	47/80 (58.8)
ASDAS clinically important improvement	50/78 (64.1)	51/72 (70.8)	50/80 (62.5)	51/74 (68.9)	51/100 (51.0)	53/85 (62.4)	48/91 (52.7)	44/78 (56.4)
ASDAS major improvement	24/78 (30.8)	30/72 (41.7)	19/80 (23.8)	29/74 (39.2)	18/100 (18.0)	27/85 (31.8)	21/91 (23.1)	26/78 (33.3)
ASDAS <2.1 (low disease activity)	35/78 (44.9)	43/72 (59.7)	35/80 (43.8)	43/74 (58.1)	20/100 (20.0)	27/85 (31.8)	16/91 (17.6)	24/78 (30.8)
ASDAS <1.3 (inactive disease)	13/78 (16.7)	18/72 (25.0)	9/80 (11.3)	16/74 (21.6)	4/100 (4.0)	10/85 (11.8)	5/91 (5.5)	4/78 (5.1)
BASDAI50	34/78 (43.6)	40/67 (59.7)	36/81 (44.4)	37/71 (52.1)	25/100 (25.0)	31/88 (35.2)	23/91 (25.3)	27/80 (33.8)
Mean change from baseline (SD)	Week 16	Week 52	Week 16	Week 52	Week 16	Week 52	Week 16	Week 52
ASDAS	-1.5 (1.1)	-1.8 (1.0)	-1.4 (0.9)	-1.7 (1.0)	-1.2 (1.0)	-1.4 (1.1)	-1.2 (1.1)	-1.5 (1.2)
BASDAI	-3.1 (2.4)	-3.6 (2.3)	-2.7 (2.0)	-3.3 (2.3)	-2.3 (2.0)	-2.9 (2.3)	-2.1 (2.4)	-2.8 (2.3)
BASFI	-2.5 (2.3)	-3.0 (2.2)	-2.5 (2.2)	-3.1 (2.4)	-1.8 (2.0)	-2.6 (2.5)	-2.1 (2.3)	-2.5 (2.3)
SF-36 PCS	8.0 (8.2)	9.4 (9.0)	8.0 (7.0)	9.0 (7.3)	6.8 (7.4)	8.0 (8.7)	6.3 (7.7)	8.2 (7.8)
ASAS Health Index	-2.3 (3.3)	-3.0 (3.2)	-2.9 (3.2)	-3.7 (3.5)	-2.2 (3.1)	-3.0 (3.8)	-1.9 (4.0)	-2.9 (3.7)
SPARCC MRI spine score	-8.9 (16.2)	-8.8 (17.3)	-8.7 (16.5)	-8.5 (15.9)	-3.2 (8.3)	NA	-5.1 (11.9)	NA
SPARCC MRI sacroiliac joint score	-3.4 (7.6)	-3.3 (8.7)	-4.1 (7.3)	-4.2 (7.5)	NA	NA	NA	NA

CRP, mg/L	-7.0 (17.0)	-9.4 (11.1)	-8.2 (15.5)	-10.2 (15.1)	-12.7 (31.7)	-10.6 (33.6)	-11.1 (19.6)	-10.4 (18.2)

ASAS, Assessment of SpondyloArthritis international Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASFI, Bath Ankylosing Spondylitis Functional Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; bDMARD, biological disease-modifying antirheumatic drug; CRP, C-reactive protein; ITT, intent-to-treat; IXE Q4W, ixekizumab 80 mg every 4 weeks; IXE Q2W, ixekizumab 80 mg every 2 weeks; MBOCF, modified baseline observation carried forward; MRI, magnetic resonance imaging; NA, not applicable; NRI, non-responder imputation; SD, standard deviation; SF-36 PCS, Medical Outcomes Study 36-item Short-Form Health Survey Physical Component Score; SPARCC, Spondyloarthritis Research Consortium of Canada; TNFi, tumour necrosis factor inhibitor.